World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
29263
World Ranking
17867
National Ranking
937

Norbert Gattermann publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Norbert Gattermann sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 468 publications — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Norbert Gattermann D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Norbert Gattermann sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Norbert Gattermann is affiliated with Heinrich Heine University Düsseldorf in Germany and has a research focus primarily in Medicine, with extensive contributions to Hematology, Genetics, Oncology, Molecular Biology, and Immunology.

The main topics covered in Gattermann's research include:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Hematological disorders and diagnostics
  • Hemoglobinopathies and Related Disorders
  • Neutropenia and Cancer Infections

Gattermann's publication record includes involvement in a number of highly specialized venues. The most frequent publication outlets are:

  • Blood
  • Cancers
  • Annals of Hematology
  • Leukemia Research
  • Deutsches Ärzteblatt international

Selected recent papers authored or co-authored by Gattermann include:

  • The evaluation of iron deficiency and iron overload, 2021, Deutsches Ärzteblatt international
  • Molecular International Prognostic Scoring System for Myelodysplastic Syndromes, 2022, NEJM Evidence
  • Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial, 2021, Leukemia
  • Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study, 2020, European Journal of Endocrinology
  • A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study, 2022, The Lancet Haematology

Frequent collaborators include researchers such as Ulrich Germing, Kathrin Nachtkamp, Annika Kasprzak, Rainer Haas, and Guido Kobbe, with collaboration counts ranging from 10 to 27 publications.

The breadth of Gattermann's research is evidenced by a substantial number of publications-over 140 in total-with a strong focus on hematological diseases, especially leukemia and related disorders. This body of work spans diagnosis, treatment, and molecular mechanisms underlying these conditions.

Best Publications

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

    Luca Malcovati;Eva Hellström-Lindberg;David Bowen;Lionel Adès

  • Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

    Hagop M. Kantarjian;Francis J. Giles;Kapil N. Bhalla;Javier A. Pinilla-Ibarz

  • The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

    Ross L. Levine;Marc Loriaux;Brian J. P. Huntly;Mignon L. Loh

  • Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

    Elsa Bernard;Yasuhito Nannya;Robert P. Hasserjian;Sean M. Devlin

  • Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

    Ulrich Germing;Norbert Gattermann;Corinna Strupp;Manuel Aivado

  • Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

    Aul C;Gattermann N;Heyll A;Germing U

  • Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.

    Andrea Kuendgen;Corinna Strupp;Manuel Aivado;Alf Bernhardt

  • Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

    Maria Domenica Cappellini;John Porter;Amal El-Beshlawy;Chi Kong Li

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

    Philipp Le Coutre;Oliver G. Ottmann;Francis Giles;Dong Wook Kim

  • Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

    John Porter;Renzo Galanello;Giuseppe Saglio;Ellis E.J. Neufeld

  • Age-related incidence and other epidemiological aspects of myelodysplastic syndromes

    C. Aul;N. Gattermann;W. Schneider

  • Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

    A Hochhaus;T Masszi;F J Giles;J P Radich

  • Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

    F. J. Giles;P. D. Le Coutre;J. Pinilla-Ibarz;R. A. Larson

  • Heteroplasmic Point Mutations of Mitochondrial DNA Affecting Subunit I of Cytochrome c Oxidase in Two Patients With Acquired Idiopathic Sideroblastic Anemia

    Norbert Gattermann;Stefan Retzlaff;Yan-Ling Wang;Götz Hofhaus

  • Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

    Alexander E. Smith;Azim M. Mohamedali;Austin Kulasekararaj;ZiYi Lim

  • Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells

    S. Geyh;S. Öz;R. P. Cadeddu;J. Fröbel

Frequent Co-Authors

Ulrich Germing
Ulrich Germing Heinrich Heine University Düsseldorf
Aristoteles Giagounidis
Aristoteles Giagounidis Heinrich Heine University Düsseldorf
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Francis J. Giles
Francis J. Giles Northwestern University
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Giuseppe Saglio
Giuseppe Saglio University of Turin
Ghulam J. Mufti
Ghulam J. Mufti King's College London
Guillermo Sanz
Guillermo Sanz Hospital Universitari i Politècnic La Fe
Oliver G. Ottmann
Oliver G. Ottmann Cardiff University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the world of medicine doesn’t stop with becoming a physician. A wide range of online degrees related to healthcare have expanded career options for students and working professionals. Programs like cheap online dnp programs allow registered nurses to advance their careers affordably and flexibly. These programs are ideal for those seeking leadership roles in clinical practice or academia.

If you’re interested in pharmacy, you can now find pharmacy school online accredited options. These offer rigorous training and meet national accreditation standards, preparing graduates for licensure and patient care responsibilities.

The demand for skilled professionals in digital health records is growing rapidly. Earning a health information technology online degree can open doors to roles in data management, cybersecurity, and compliance within healthcare systems.

For those looking to enter the administrative side of healthcare, getting a medical billing and coding certification cost can provide a quick and affordable entry point. These certifications are ideal for remote work and addressing the growing need for accurate medical recordkeeping.

Best Scientists Citing Norbert Gattermann

Trending Scientists

Recently Published Articles